Image Ben Hargreaves R&D Data-driven disease research harnessing the genome Ben Hargreaves speaks to the UK Biobank to learn more about their work building a dataset of 500,000 individuals. R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident. Patients The rapidly evolving role of patient organisations Ben Hargreaves finds that patient organisations are providing an increasingly essential role as a linker between patients and the rest of the life sciences industry. R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Load more results
R&D Data-driven disease research harnessing the genome Ben Hargreaves speaks to the UK Biobank to learn more about their work building a dataset of 500,000 individuals.
R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.
Patients The rapidly evolving role of patient organisations Ben Hargreaves finds that patient organisations are providing an increasingly essential role as a linker between patients and the rest of the life sciences industry.
R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.